Diagnosis and management of liver abscess pose challenges in low-resource settings, necessitating innovative approaches and resource-adapted strategies to improve patient outcomes and reduce disease burden in underserved populations.
March 2022
Significant reduction in choroidal thickness is observed within weeks after COVID-19 infection, suggesting potential ocular manifestations of the disease and the need for long-term monitoring of ocular health in recovered patients.
March 2022
Interdisciplinary team conducts a narrative literature review to identify key issues in the clinical management of COVID-19 patients after intensive care, highlighting the need for comprehensive post-ICU care strategies to optimize patient outcomes.
March 2022
Initiative aims to help patients and clinicians choose evidence-based care during the COVID-19 pandemic, promoting shared decision-making and informed choices to optimize patient outcomes and resource utilization.
March 2022
Perinatal SARS-CoV-2 infection poses risks to neonates and mothers, highlighting the importance of early detection, preventive measures, and supportive care to optimize maternal and neonatal outcomes during the COVID-19 pandemic.
March 2022
Update on lead poisoning explores its effects on blood pressure levels and the rationale for intervention strategies to reverse its adverse health effects, emphasizing the importance of environmental health policies in lead exposure prevention.
March 2022
Practice patterns in the surgical management of small neuroendocrine tumors of the pancreas are examined, with a focus on comparing postoperative outcomes between resection and enucleation procedures to inform treatment decision-making and optimize patient care.
March 2022
High rates of Chlamydia trachomatis infection are recorded in young people, underscoring the need for targeted interventions and comprehensive sexual health education to reduce the incidence and transmission of sexually transmitted infections in this population.
March 2022
Early use of nitazoxanide in mild COVID-19 disease is safe and significantly reduces viral load, suggesting a potential role for this antiparasitic agent in the treatment of SARS-CoV-2 infection, pending further clinical trials to confirm efficacy.
March 2022